Evaluation of prognostic factors in liver-limited metastatic colorectal cancer: a preplanned analysis of the FIRE-1 trial

Por Giessen, C, Fischer von Weikersthal, L, Laubender, R P, Stintzing, S, Modest, D P, Schalhorn, A, Schulz, C, Heinemann, V
Publicado em 2013

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorect...

Por Modest, D. P., Ricard, I., Heinemann, V., Hegewisch-Becker, S., Schmiegel, W., Porschen, R., Stintzing, S., Graeven, U., Arnold, D., von Weikersthal, L. F., Giessen-Jung, C., Stahler, A., Schmoll, H. J., Jung, A., Kirchner, T., Tannapfel, A., Reinacher-Schick, A.
Publicado no Ann Oncol (2016)

Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy:...

Por von Einem, J. C., Heinemann, V., von Weikersthal, L. Fischer, Vehling-Kaiser, U., Stauch, M., Hass, H. G., Decker, T., Klein, S., Held, S., Jung, A., Kirchner, T., Haas, M., Holch, J., Michl, M., Aubele, P., Boeck, S., Schulz, C., Giessen, C., Stintzing, S., Modest, D. P.
Publicado em 2014